SYDNEY, Australia, March 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$686,704 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2017 fiscal year, mainly related to the Company’s TACTI-mel trial, a Phase I clinical study in melanoma using its lead compound eftilagimod alpha (“IMP321”), conducted in Australia.

This follows approval from AusIndustry of Immutep’s application for an Advance/Overseas Finding. Due to the Advance Finding, Immutep’s projected research and development activities for TACTI-mel in both Australia and overseas are eligible for the R&D Tax Incentive for a period of three years to 30 June 2019.

Immutep will apply the funding towards furthering its current active clinical trial program for lead product, IMP321.

About Immutep

Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the U.S.  For further information please visit www.immutep.com

For further information please contact:
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com

U.S. Investors:
Jay Campbell, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.